Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.79 -3.2%	$1.56	$1.05 ▼ $5.17	$200.41M	0.3	1.47 million shs	995,478 shs
ALTS ALT5 Sigma	$5.48 -10.5%	$7.68	$1.55 ▼ $10.95	$132.25M	2.17	7.71 million shs	15.58 million shs
ATNM Actinium Pharmaceuticals	$1.65 -3.5%	$1.58	$1.03 ▼ $2.41	$51.47M	-0.53	420,074 shs	96,492 shs
CCCC C4 Therapeutics	$2.76 -3.5%	$1.94	$1.09 ▼ $7.22	$203.55M	2.97	1.62 million shs	1.26 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-1.07%	+12.80%	+14.91%	+37.04%	+55.46%
ALTS ALT5 Sigma	+3.03%	-7.27%	-16.39%	-9.87%	+169.60%
ATNM Actinium Pharmaceuticals	+1.18%	+16.33%	0.00%	-6.56%	-6.04%
CCCC C4 Therapeutics	+16.26%	+18.43%	+23.28%	+93.24%	-51.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.6833 of 5 stars	3.6	3.0	2.1	1.7	0.6
ALTS ALT5 Sigma	0.6194 of 5 stars	0.0	4.0	3.1	0.0	0.0
ATNM Actinium Pharmaceuticals	2.9331 of 5 stars	3.5	5.0	2.8	0.0	0.6
CCCC C4 Therapeutics	1.7939 of 5 stars	3.2	2.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	386.83% Upside
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	172.73% Upside
CCCC C4 Therapeutics	2.33	Hold	$8.00	189.86% Upside

Current Analyst Ratings Breakdown

Latest ATNM, ALTS, CCCC, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	10.36	N/A	N/A	$1.22 per share	1.47
ALTS ALT5 Sigma	$12.53M	9.45	N/A	N/A	$0.55 per share	9.96
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
CCCC C4 Therapeutics	$35.58M	5.52	N/A	N/A	$2.45 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.37	0.00	N/A	N/A	-802.03%	-34.01%	-24.18%	11/5/2025 (Estimated)
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
CCCC C4 Therapeutics	-$105.32M	-$1.58	0.00	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)

Latest ATNM, ALTS, CCCC, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$1.34 million	$1.78 million
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.88	3.88
ALTS ALT5 Sigma	1.45	0.88	0.88
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
CCCC C4 Therapeutics	N/A	5.06	5.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ALTS ALT5 Sigma	6.27%
ATNM Actinium Pharmaceuticals	27.50%
CCCC C4 Therapeutics	78.81%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	5.60%
ALTS ALT5 Sigma	4.90%
ATNM Actinium Pharmaceuticals	6.00%
CCCC C4 Therapeutics	8.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.33 million	102.27 million	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable

ATNM, ALTS, CCCC, and ACRS Headlines

Recent News About These Companies

FY2028 EPS Forecast for C4 Therapeutics Lowered by Analyst

August 12, 2025 | marketbeat.com

CCCC Revenue Drops 46%

August 12, 2025 | theglobeandmail.com

Wall Street Zen Downgrades C4 Therapeutics (NASDAQ:CCCC) to Sell

August 10, 2025 | marketbeat.com

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

August 7, 2025 | zacks.com

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025 | globenewswire.com

C4 Therapeutics (CCCC) Expected to Announce Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

June 16, 2025 | seekingalpha.com

C4 Therapeutics Shelves BRAF Blocker, Goes All-In on Multiple Myeloma Drug

May 7, 2025 | biospace.comB

C4 Therapeutics reports Q1 EPS (37c), consensus (42c)

May 7, 2025 | msn.com

Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 12.77%

May 7, 2025 | aaii.comA

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025 | finanznachrichten.de

C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide

May 7, 2025 | fiercebiotech.comF

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025 | globenewswire.com

C4 Therapeutics Inc. CCCC (U.S.: Nasdaq)

May 1, 2025 | wsj.com

Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 17.60%

April 22, 2025 | aaii.comA

Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 10.31%

April 2, 2025 | aaii.comA

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

March 10, 2025 | seekingalpha.com

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 3, 2025 | zacks.com

C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 1, 2025 | finanznachrichten.de

Stifel Nicolaus Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, ALTS, CCCC, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.79 -0.06 (-3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.77 -0.02 (-1.06%)

As of 07:57 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ALT5 Sigma NASDAQ:ALTS

$5.48 -0.64 (-10.46%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 +0.02 (+0.36%)

As of 07:59 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Actinium Pharmaceuticals NYSE:ATNM

$1.65 -0.06 (-3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 -0.02 (-1.21%)

As of 06:04 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

C4 Therapeutics NASDAQ:CCCC

$2.76 -0.10 (-3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.77 +0.01 (+0.33%)

As of 07:58 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time